<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung</forename><forename type="middle">Yong</forename><surname>Oh</surname></persName>
							<idno type="ORCID">0000-0002-8321-4113</idno>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won</forename><forename type="middle">Seog</forename><surname>Kim</surname></persName>
							<idno type="ORCID">0000-0002-8321-4113</idno>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><forename type="middle">Seok</forename><surname>Kim</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seok</forename><forename type="middle">Jin</forename><surname>Kim</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dok</forename><forename type="middle">Hyun</forename><surname>Yoon</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deok-Hwan</forename><surname>Yang</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won</forename><forename type="middle">Sik</forename><surname>Lee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyo</forename><forename type="middle">Jung</forename><surname>Kim</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ho-Young</forename><surname>Yhim</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Seong</roleName><forename type="first">Hyun</forename><surname>Jeong</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><surname>Ho Won</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suee</forename><surname>Lee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyun</forename><surname>Jee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Kong</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung-Nam</forename><surname>Lim</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><surname>Ho</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ji</forename><surname>13</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyung</forename><forename type="middle">A</forename><surname>Kwon</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gyeong-Won</forename><surname>Lee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae</forename><forename type="middle">Hoon</forename><surname>Lee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sup</forename><surname>Ho</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Lee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ho-Jin</forename><surname>Shin</surname></persName>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheolwon</forename><surname>Suh</surname></persName>
							<email>csuh@amc.seoul.kr</email>
						</author>
						<author>
							<affiliation>
								<orgName>4 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, </orgName>
								<address><addrLine>Songpa-gu, Seoul 05505, Republic of Korea Busan 49201, Republic of Korea. Seoul 06351, Republic of Korea. Seoul 03722, Republic of Korea. Songpa-gu, Seoul 05505, Republic of Korea. Hwasun 58128, Republic of Korea. Busan 04511, Republic of Korea. Anyang 14068, Republic of Korea. Jeonju 54907, Republic of Korea. Suwon 16499, Republic of Korea. Seoul 04401, Republic of Korea. Wonju 26426, Republic of Korea. Busan 48108, Republic of Korea. Changwon 51353, Republic of Korea. Busan 46033, Republic of Korea. Jinju 52727, Republic of Korea. Incheon 21565, Republic of Korea. Busan 49267, Republic of Korea. Busan 49241, Republic of Korea.</addrLine></address>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 1 Department of Internal Medicine, Dong-A University Hospital, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 2 Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 3 Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 4 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 5 Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 6 Department of Hematology, Busan Paik Hospital, Inje University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 7 Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 8 Department of Internal Medicine, Chonbuk National University Hospital, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 9 Department of Hematology-Oncology, Ajou University School of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 10 Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 11 Division of Hematology-Oncology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 12 Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 13 Division of Hematology and Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 14 Division of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 15 Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 16 Department of Internal Medicine, Gachon University Gil Medical Center, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 17 Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, </orgName>
							</affiliation>
						</author>
						<author>
							<affiliation>
								<orgName> 18 Division of Oncology, Department of Internal Medicine, Pusan National University Hospital,</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1186/s40880-019-0403-7</idno>
					<note type="submission">Received: 4 May 2019 Accepted: 24 September 2019</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>Background: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single-arm, open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation. Methods: Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL. Rituximab (375 mg/m 2), cyclophosphamide (750 mg/m 2), and vincristine (1.4 mg/m 2 ; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (100 mg) was given on days 1-5 of each 3-week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R-CVP treatment, were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m 2 every 8 weeks for up to 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety. Results: 47 patients were enrolled, of whom, 45 (96%) received rituximab-maintenance treatment. Fifteen (33%) patients had nodal MZL. Following R-CVP first-line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively. After a median follow-up of 38.2 months, their observed 3-year PFS rate was 81%. During the rituximab-maintenance, 6 PR and 1 SD patients achieved CR following the administration of R-CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (P = 0.003) and demonstrated a 3-year OS rate of 90%. Rituximab-maintenance therapy was well tolerated, and the common treatment-emergent adverse events were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%).</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>Marginal zone lymphoma (MZL) is a B cell non-Hodgkin's lymphoma (NHL) that accounts for approximately 5%-17% of all NHL in adults <ref type="bibr" target="#b0">[1]</ref>. In Korea, MZL is the second most frequent histological NHL subtype after diffuse large B-cell lymphoma, constituting one-fifth of all NHL cases <ref type="bibr" target="#b1">[2]</ref>. The three major subtypes of MZL defined by the World Health Organization (WHO)-are splenic MZL, mucosa-associated lymphoid tissue (MALT) MZL, and nodal MZL <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>, which are determined by the anatomical location of disease-initiating B-cells <ref type="bibr" target="#b4">[5]</ref>. MALT is the most common MZL subtype, with an estimated 5-year overall survival (OS) and progression-free survival (PFS) &gt; 90% and 70% while nodal MZL has been associated with most frequent relapse cases <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>. Overall, MZL is characterized by an indolent clinical course <ref type="bibr" target="#b4">[5]</ref>, yet remission is often followed by multiple relapses <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>, highlighting the need for tolerable maintenance treatments that can extend the remission periods induced by first-line therapies.</p><p>In B-cell malignancies, rituximab (Mabthera ® ; Roche, Basel, Switzerland) was the first targeted therapy drug which caused a paradigm shift in disease treatment <ref type="bibr" target="#b10">[11]</ref>. Rituximab is a chimeric, monoclonal antibody targeting CD20, a cell surface antigen expressed during most stages of B-cell development <ref type="bibr" target="#b11">[12]</ref>, and is found on 95% of B-cell lymphoma cells <ref type="bibr" target="#b12">[13]</ref>. The clinical efficacy of rituximab was first demonstrated in follicular lymphoma (FL) <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref> and it has since been prescribed for other subtypes of NHL, including MZL, with promising results <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>. In this study, we evaluated rituximab as a candidate maintenance therapy in patients with advanced MZL.</p><p>In MZL, the clinical activity of rituximab as a single agent therapy has been studied in a small, retrospective case study and phase II studies, which have demonstrated improved safety and outcomes with rituximab-monotherapy <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>. However, in a phase II study conducted by the International Extranodal Lymphoma Study Group (IELSG), patients with MALT lymphomas did not respond to treatment within 14-22 months <ref type="bibr" target="#b17">[18]</ref>. However, numerous studies have demonstrated the efficacy and tolerability of rituximab in combination with chemotherapy regimens, with an overall improved response rate of up to 90%-100% <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>. A phase III study of rituximab in combination with chlorambucil (R-Cb) comparing the efficacy of R or Cb monotherapies against R-Cb combination treatment showed that the group receiving combination treatment had superior 5-year event-free survival (68% with R-Cb vs. 50% with R vs. 51% with Cb, P &lt; 0.001) <ref type="bibr" target="#b24">[25]</ref>. For patients who have received first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone) combination immunochemotherapy, the efficacy and safety of the regimen has been demonstrated in patients with untreated stage III-IV MZL, in the context of a phase II study conducted by the Consortium for Improving Survival of Lymphoma (CISL) <ref type="bibr" target="#b23">[24]</ref>. The overall response rate achieved with R-CVP in the previous CISL study was 88%, with 60% of patients achieving complete response (CR) <ref type="bibr" target="#b23">[24]</ref>. The 3-year PFS and OS rates were 59% and 95%, respectively <ref type="bibr" target="#b23">[24]</ref>. In another phase II trial, R-B (rituximab-bendamustine) treatment for patients with MALT lymphoma, also reported a 100% CR and 87.7% event-free survival rate at 7 years after treatment (95% CI 76.0-94.0) <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref>.</p><p>Despite the improved response and progression or event-free survival rates achieved with first-line rituximab-containing regimens, relapses still persist once the treatment is completed <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>. Typically, patients suffer multiple relapses, and subsequent lines of therapy for MZL patients achieve progressively shorter responses <ref type="bibr" target="#b8">[9]</ref>, therefore, extending the period of remission for MZL patients remains an essential goal. One potential strategy is the use of maintenance therapy once a response has been achieved with first-line therapy. Several NHL studies have previously evaluated rituximab as a maintenance agent <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>. FL patients who receive rituximab-maintenance therapy after responding to first-line rituximab and chemotherapy experience significantly longer PFS compared to those receiving standard treatment <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>. Similar results were reported for the randomized phase III primary rituximab and maintenance (PRIMA) trial, in which 2 years of rituximab-maintenance therapy significantly improved the 6-year PFS in FL patients who responded to first-line rituximab and chemotherapy combination treatment, compared to patients on standard therapy [R-CVP or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)] alone <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p>Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial registration clinicaltrials.gov: NCT01213095</head><p>Keywords: Marginal zone, Lymphoma, Advanced stage, Rituximab, Cyclophosphamide, Vincristine, Maintenance, Multicenter, Open label, Survival</p><p>The studies described above indicate that adding rituximab-maintenance therapy to a rituximab-based immunochemotherapeutic regimen may be an effective strategy for extending remission in patients with advanced MZL. Here we report the results of a phase II study evaluating the effect of rituximab-maintenance treatment following R-CVP as a first-line therapy on the survival of MZL patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design and participants</head><p>This was a multicenter, open-label, non-comparative phase II study conducted in medical centers across South Korea (ClinicalTrials.gov identifier NCT01213095). Patients aged ≥ 20 years with histologically confirmed, Ann Arbor stage III-IV, CD20-positive MZL were eligible for this study. The patients who had achieved CR, partial response (PR), or stable disease (SD) after 6 or 8 cycles of first-line R-CVP combination therapy, as defined by the revised International Working Group (IWG) response criteria for malignant lymphoma were enrolled to the R-maintenance clinical trial <ref type="bibr" target="#b31">[32]</ref>.</p><p>Enrolment was possible even without symptom for first-line treatment with R-CVP. Other eligibility criteria were presence of at least one bi-dimensionally measurable lesion (≥ 2 cm by conventional computed tomography [CT], ≥ 1 cm by spiral CT, ≥ 2 cm skin lesion, or ≥ 2 cm on physical examination) at first line R-CVP treatment; had an Eastern Clinical Oncology Group (ECOG) performance status (PS) score ≤ 2; and adequate renal, liver and bone marrow (BM) functions at baseline of R-maintenance enrollment.</p><p>Patients who had received prior chemotherapy or radiotherapy for MZL were excluded from the study, as were those with a large cell component &gt; 10%, central nervous system involvement, or previous malignancy in the past 5 years with the exceptions of curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix uteri, or thyroid cancer with completed active treatment and no evidence of recurrence over a period of 1 year. Informed consent was obtained from all patients for their participation in the study. Informed consent and patients' enrolment were acquired after the first line R-CVP treatment. Investigators clearly discussed with the patients for their treatment option including "watchful wait". This clinical trial obtained informed consents for R-maintenance treatment. This study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines. The study design was reviewed and approved by the relevant independent ethics committees for each investigational site. All authors had access to primary clinical trial data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedures</head><p>Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy. Rituximab (Roche Pharm Co., Ltd., Basel, Switzerland) (375 mg/m 2 ), cyclophosphamide (Bukwang Pharm Co., Ltd, Seoul, Korea) (750 mg/m 2 ), and vincristine (1.4 mg/ m 2 ; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (Yuhan Corporation Co., Ltd, Seoul, Korea) (100 mg) was given on days 1-5 of each 3-week cycle. Screening assessments of tumor response before initiating rituximab-maintenance were performed on day 21 of the final R-CVP cycle, and within the 14 days prior to the first dose of rituximab-maintenance treatment.</p><p>Rituximab-maintenance therapy was administered intravenously at a dose of 375 mg/m 2 every 8 weeks for up to 12 cycles. To enhance infusion safety, infusion rates and premedication were administered according to the rituximab's prescribing information <ref type="bibr" target="#b32">[33]</ref>. Tumor responses were assessed according to the IWG criteria <ref type="bibr" target="#b31">[32]</ref> at screening and following every two cycles of rituximab-maintenance therapy, or when disease progression was suspected. Evaluation of response to therapy included physical examination, serum lactate dehydrogenase (LDH), CT or magnetic resonance imaging of initially involved sites, and positron emission tomography (PET) or PET-CT. In cases of initial BM involvement, bilateral BM aspiration and biopsies were performed after chemotherapy completion to confirm CR.</p><p>Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 4.03). Safety monitoring continued up to 30 days after the final cycle of rituximab-maintenance. Follow-up was continued for 3 years after completing the study treatment, and the tumors were assessed in imaging studies performed every 6 months until disease progression was detected, at which point information on survival and new lymphoma treatment were updated every 6 months until death.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcomes</head><p>The primary endpoint was 3-year PFS, defined the length of time during and after the R-CVP treatment of MZL that a patient lives with the disease but it does not get worse. Secondary endpoints were (1) overall survival (OS), defined from the length of time of R-CVP treatment commencement until death due to any cause or the date of the last follow-up, and (2) treatment safety.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p>This trial was designed according to the Simon "optimal" design for phase II trials and aimed to determine whether rituximab-maintenance following R-CVP could improve PFS <ref type="bibr" target="#b32">[33]</ref>. Based on literature analyses <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b23">24]</ref>, the baseline 3-year PFS rate was expected to be 50%, with an anticipated treatment difference of 20%. Assuming a drop-out rate of 10%, a total of 47 patients were required to achieve a power of 80% to detect a 20% treatment difference with an alpha of 0.05. PFS was defined as the time R-CVP treatment started to the first recorded incidence of relapse, disease progression, death due to any cause, or last date of follow up for the enrolled patients who did not progress.</p><p>The intent-to-treat population (for efficacy analysis) and safety population (for safety analysis) both included enrolled patients who received at least one dose of rituximab-maintenance therapy. Time-to-event data were estimated using the Kaplan-Meier method. The Cox proportional hazards model was used to estimate the hazard ratio (HR) and the corresponding 95% CI with regard to the low-risk group. All reported P values were twosided, and a P value &lt; 0.05 was considered significant. All analyses were conducted using the Statistical Package for Social Sciences version 20.0 for Windows (SPSS Inc., Chicago, IL, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>A total of 47 patients were enrolled into this trial from a total of 18 centers, of whom, 45 (96%) received rituximab-maintenance treatment. One (2%) patient failed screening due to thyroid cancer, and one (2%) patient withdrew consent <ref type="figure" target="#fig_0">(Fig. 1)</ref>. The first patient of the trial was enrolled on October 19, 2010, and the date of last follow-up was on February 4, 2016. In total, 34 (72%) patients completed the planned 12 cycles of rituximabmaintenance therapy <ref type="figure" target="#fig_0">(Fig. 1)</ref>. Six (13%) patients discontinued due to progressive disease (PD), while two (4%) discontinued due to AEs, one (2%) was lost to follow-up, one (2%) withdrew consent, and one (2%) died (pneumonia, after 11 cycles) prior to the rituximab-maintenance treatment completion.</p><p>Baseline patient demographics and disease characteristics are summarized in <ref type="table" target="#tab_0">Table 1</ref>. The median age was 54 years (range, 33-77 years), and 43 (96%) patients had an ECOG performance score ≤ 1. In total, 15 (33%) patients had nodal MZL and 30 (67%) had MALT MZL. Following R-CVP first-line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively ( <ref type="table" target="#tab_0">Table 1)</ref>. The number of patients who received 6 or 8 cycles of prior R-CVP therapy were 10 (22%) and 35 (78%), respectively <ref type="table" target="#tab_0">(Table 1)</ref>.</p><p>After a median follow-up of 38.2 months, the 3-year PFS rate was found to be 81% <ref type="figure" target="#fig_1">(Fig. 2)</ref>. During the rituximab-maintenance therapy, 6 PR patients and 1 SD patient achieved CR following R-CVP. Univariate analyses showed that elevated LDH (HR 6.819; 95% CI 1.885-24.667; P = 0.003) and the presence of B symptoms (HR 0.130; 95% CI 0.034-0.500; P = 0.003) to be significant prognostic factors for PFS following rituximab-maintenance ( <ref type="table" target="#tab_1">Table 2)</ref>. MZL subtype was not a significant prognostic factor for PFS, nor was response to R-CVP (CR vs. &lt; CR; <ref type="table" target="#tab_1">Table 2</ref>). After a median follow-up of 38.2 months, the 3-year OS rate was found to be 90% <ref type="figure">(Fig. 3)</ref>.</p><p>A total of 51 treatment-emergent AEs (TEAEs) were reported during the study, the majority of which were grade 1 or 2 ( <ref type="table" target="#tab_2">Table 3)</ref>. Of the two patients who discontinued the treatment due to AEs, one experienced abdominal pain and the other had recurrent pneumonia. In total, four deaths occurred during the study (one sepsis, one PD, and two pneumonia), one (pneumonia) of which was related to the treatment. TEAEs experienced by more than one patient are summarized in <ref type="table" target="#tab_2">Table 3</ref>. The most frequent treatment-related TEAEs were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%). All cases of sensory neuropathy and myalgia were of grade 1 or 2. Of the four cases who experienced fatigue, two were of grade 1 and two were of grade 3, while three of the four cases of neutropenia were classified as grade 3-4. and subsequent lines of therapy achieve incrementally shorter responses <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>. Therefore, extending the period of remission induced by first-line therapies is an essential goal in the treatment of MZL. The current multicenter study evaluated the efficacy and safety of 2 years of rituximab-maintenance therapy in stage III-IV MZL patients who had previously been treated with 6 or 8 cycles of R-CVP combination therapy. Here, rituximab-maintenance following first-line R-CVP therapy led to 3-year PFS and OS survival rates of 81% and 90%, respectively. Univariate analyses identified elevated LDH and the presence of B symptoms as significant prognostic factors for PFS. Rituximab-maintenance treatment following rituximab-based immunochemotherapy was generally tolerable in this study, indicating that rituximab-maintenance treatment is a viable option for MZL patients. Except for the 4 cases of neutropenia above of grade 3, other non-hematologic toxicities were mild. In addition, we hypothesized that several of the presented symptoms-sensory neuropathy, fatigue, and myalgia-could have been originated prior to R-CVP immunochemotherapy induction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Historically, given the typically slow progression and poor curability of MZL, patients with advanced disease have been subjected to a "watch-and-wait" approach, whereby treatment is delayed until the patients' disease progress or becomes symptomatic <ref type="bibr" target="#b29">[30]</ref>. Numerous studies have asked the question of whether treatment with rituximab may be a more suitable approach for these patients. Indeed, rituximab single-agent therapy has been shown to provide clinical benefit in NHL, including MZL, which can be improved upon combination with  chemotherapeutic regimens-fludarabine, chlorambucil, CVP, and bendamustine, which has been summarized as shown in <ref type="table" target="#tab_3">Table 4</ref>  <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref>. The efficacy and safety of a first-line R-CVP immunochemotherapy regimen were demonstrated in patients with previously untreated stage III-IV MZL in a phase II study conducted by CISL <ref type="bibr" target="#b23">[24]</ref>. In this previous CISL study, following 6-8 three-weekly cycles of R-CVP, the 3-year PFS and OS rates were 59% and 95%, respectively. In comparison to the present study, an equivalent R-CVP regimen followed by rituximab-maintenance therapy resulted in a 3-year PFS rate over 20% higher (81% vs. 59%) than the CISL study. The OS of the 2 studies did not differ substantially (previous vs. current CISL studies, 95% vs. 90%, respectively), which may have been as a  result of the short follow-up duration and small sample size of the present study.</p><p>There is growing evidence of improved outcomes among NHL populations after rituximab-maintenance therapy ( <ref type="table" target="#tab_4">Table 5)</ref>. A randomized phase II study comparing rituximab-maintenance or retreatment in 114 NHL patients who had previously been treated with chemotherapy reported significantly longer PFS in the rituximab-maintenance group comparing observation group until progression (31.3 vs. 7.4 months) <ref type="bibr" target="#b30">[31]</ref>. Rituximabmaintenance therapy has also been evaluated following induction with rituximab-monotherapy in patients with stage III-IV small lymphocytic lymphoma and MZL patients in the randomized phase III rituximab extended schedule or retreatment (RESORT) trial <ref type="bibr" target="#b29">[30]</ref>. In patients who responded to rituximab-induction, the median time for treatment failure was significantly improved from 1.4 years with rituximab retreatment at disease progression to 4.8 years with rituximab-maintenance <ref type="bibr" target="#b29">[30]</ref>. Furthermore, rituximab-maintenance significantly improved the PFS of FL patients following rituximab-based firstline immunochemotherapy <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29]</ref>.</p><p>Although the current study did not contain a reference arm, sustained rituximab treatment is likely to have resulted in an overall higher total dose of rituximab in patients receiving maintenance treatment. Indeed, the investigators in the phase III RESORT study estimated a three-fold higher rituximab dose in their  maintenance group compared to patients receiving retreatment only <ref type="bibr" target="#b29">[30]</ref>. The lack of a direct comparator in this study means statistical analyses cannot be performed to evaluate the effects of adding rituximabmaintenance to R-CVP first-line therapy at this stage. Furthermore, only one rituximab-maintenance duration was evaluated in this study, which has been shown to impact efficacy. The randomized phase III SAKK 35/03 study, which compared short-term (8 months) and long-term (up to 5 years) administration of bi-monthly rituximab-maintenance following rituximab-monotherapy in patients with FL, found that long-term maintenance therapy increased toxicity without improving the event-free survival or OS <ref type="bibr" target="#b33">[34]</ref>. Additional randomized controlled trials are required to fully evaluate the role of R maintenance. In the MAINTAIN trial, patients having induction therapy were treated with up to 6 cycles of bendamustine plus rituximab (B-R) plus two additional R cycles. Only patients responding to B-R were then randomized to either R maintenance (q 2 months for 2 years) or observation. The PFS was superior for 2 years of R maintenance therapy, with the median not yet reached vs. 92.2 months for observation (P = 0.008).</p><p>The OS rate at 6 years was 92% for R maintenance therapy vs. 86% for observation <ref type="bibr" target="#b34">[35]</ref>. Another CD20-targeting immunotherapy-obinutuzumab-is currently being compared with rituximab as maintenance therapy following immunochemotherapy in advanced, CD20positive indolent FL and MZL patients <ref type="bibr" target="#b35">[36]</ref>. In this study, there are several crucial points that require interpretations. The patients' pathology and imaging, including PET-CT, results were not reviewed centrally. The relatively high rate of treatment discontinuation in this study is a potential caveat. In total, 14 (30%) of the 47 eligible patients enrolled in this study discontinued for reasons such as withdrawn consent, disease progression, AEs, loss to follow-up, or death. Combined with the small target sample size, this high proportion of discontinuations means that conclusions for this study are based on a limited population size. In addition, splenic MZL, which is well-controlled with rituximab monotherapy and maintenance <ref type="bibr" target="#b36">[37]</ref>, was not included in our study due to it being extremely rare in Korea. Therefore, further study with new novel agents and randomized designed phase III investigating the role of maintenance and induction regimen is needed for improving the survivals of MZL patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>In conclusion, this single-arm, open-label, multicenter phase II study of rituximab-maintenance following firstline R-CVP therapy demonstrated good PFS in patients with advanced-stage MZL, with tolerable toxicities.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc>MZL, despite being heterogeneous malignancy and mostly indolent, its disease characteristics, clinical picture, and treatment algorithms vary considerably based on the subtype and site of involvement. Relapses are frequent, Enrolled (N = 47) Commenced Rituximab-maintenance treatment (N = 45) Completed 12 cycles of Rituximab-maintenance (N = 34) Excluded (n = 2) • Failed screening (n = 1) • Withdrew consent (n = 1) Discontinued study treatment (n = 11) • PD (n = 6) • AE (n = 2) • Lost to follow-up (n = 1) • Withdrew consent (n = 1) • Sudden death (n = 1) Patient disposition. Flow chart showing the number of patients who were enrolled, commenced rituximab-maintenance treatment, and completed the rituximab-maintenance treatment. AE adverse event, PD progressive disease</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc>PFS following R-CVP and rituximab-maintenance therapy in the intent-to-treat population. Kaplan-Meier plot of PFS in patients with advanced MZL treated with rituximab-maintenance following first-line R-CVP therapy. MZL marginal zone lymphoma, PFS progression-free survival, R-CVP rituximab cyclophosphamide vincristine prednisolone</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 Baseline demographics and disease characteristics in the intent-to-treat population</head><label>1</label><figDesc>are expressed as n (%) unless indicated otherwise BM bone marrow, CR complete response, ECOG Eastern Clinical Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, MALT mucosa-associated lymphoid tissue, MZL marginal zone B-cell lymphoma, PR partial response, R-CVP rituximab cyclophosphamide vincristine prednisolone, SD stable disease a Fever, night sweats, and/or weight loss b One case each in the kidney, liver, nasal cavity, subcutaneous tissue, and small intestine</figDesc><table><row><cell>Values</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 Univariate analyses of prognostic factors for PFS in the intent-to-treat population</head><label>2</label><figDesc>bone marrow, CR complete response, CI confidence interval, ECOG Eastern Clinical Oncology Group, HR hazard ratio, IPI International Prognostic Index, LDH lactate dehydrogenase, MZL marginal zone B-cell lymphoma, PFS progression-free survival, R-CVP rituximab cyclophosphamide vincristine prednisolone a Fever, night sweats, and/or weight loss</figDesc><table><row><cell>Gender (male vs. female) Age (&lt; 60 years vs. ≥ 60 years) ECOG performance status (0-1 vs. 2-3) Ann Arbor stage (III vs. IV) Elevated LDH (no vs. yes) BM involvement (absent vs. present) B symptoms a (present vs. absent) IPI score (1 vs. 2-4) Extranodal MZL (present vs. absent) BM Variable R-CVP response (CR vs. &lt; CR)</cell><cell>N/n 32/13 29/16 43/2 11/34 38/7 34/11 7/38 13/32 30/15 20/25</cell><cell>PFS HR 0.025 2.663 4.756 31.820 6.819 3.313 0.130 4.951 0.570 0.388</cell><cell>95% CI 0.000-6.051 0.743-9.540 0.582-38.870 0.072-13993.516 1.885-24.667 0.862-12.736 0.034-0.500 0.622-39.401 0.157-2.062 0.097-1.544</cell><cell>P value 0.187 0.132 0.146 0.265 0.003 0.081 0.003 0.131 0.391 0.179</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 Summary of TEAEs (safety population)</head><label>3</label><figDesc></figDesc><table><row><cell>Values are expressed as n (%)</cell></row><row><cell>TEAE treatment-emergent adverse event</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 First-line immunochemotherapy for marginal zone lymphoma</head><label>4</label><figDesc>progression-free survival, OS overall survival, CR complete response, PR partial response, MZL marginal zone B-cell lymphoma, MALT mucosa-associated lymphoid tissue, R-CVP rituximab-cyclophosphamide, vincristine, and prednisolone, R-Cb rituximab-chlorambucil, R-B rituximab-bendamustine a Event-free survival</figDesc><table><row><cell>Regimen R-fludarabine Zucca et al. [23, 25] R-Cb Salar et al. [19] Kang et al. [24] R-CVP Salar et al. [26, 27] R-B by R-mainte-nance PFS Study Oh (present study) R-CVP followed</cell><cell>Disease type Any stage MALT lymphoma Any stage MALT lymphoma Stage III/IV MZL Any stage MALT lymphoma Stage III/IV MZL</cell><cell>Trial phase type II III (R-Cb vs R vs Cb) 132 (total 401) 94.7% (78.8 + 15.9) 5-year, 68% a 5-year, 90% No. of patients Overall RR (CR + PR) PFS OS 22 100% (62 + 38) 2-year, 88% 2-year, 100% II 41 87.5% (60 + 27.5) 3-year, 59% 3-year, 94% II 57 100% 7-year, 92.8% 7-year, 94.7% II 45 -3-year, 81% 3-year, 90%</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5 Rituximab maintenance therapy for indolent lymphoma</head><label>5</label><figDesc>progression-free survival, EFS event-free survival, TTP time to progression, PD progression of disease, MZL marginal zone B-cell lymphoma, FL follicular lymphoma, SLL small lymphocytic lymphoma, R rituximab, MALT mucosa-associated lymphoid tissue, R-CVP rituximab-cyclophosphamide, vincristine, and prednisolone, R-CHOP rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone, R-FCM rituximab-fludarabine, cyclophosphamide, and mitoxantrone, R-Cb rituximabchlorambucil, R-B rituximab-bendamustine</figDesc><table><row><cell>Hainsworth et al. [31] Williams et al. [30] Taverna et al. [37] Salles et al. [28] Rummel et al. [35] study) PFS Study Oh (present</cell><cell>Disease, treatment FL/SLL SLL/MZL FL (including relapse) FL MZL MZL</cell><cell>Induction treatment R weekly (4 times) R weekly (4 times) R weekly (4 times) R-CVP/R-CHOP/R-FCM R-B + 2R R-CVP</cell><cell>Maintenance schedule 4 weeks R q 6 months × 4 times R q 3 months till PD R q 2 months for 8 month vs 5 years R q 2 months for 2 years R q 2 months for 2 years for 2 years R q 2 months</cell><cell>Trial design No. of patients Randomized phase II 114 Phase III 128 Phase III 165 Phase III 1019 Randomized phase II 104 Phase II 45</cell><cell>Outcomes PFS (median) 31.3 months 7.4 months Study arm Control arm P value 0.007 TTP (median) 4.8 years 1.4 years 0.012 EFS 3.4 years (8 months) 5.3 year (5 years) 0.14 PFS (3 years) 74.9% 57.6% &lt; 0.0001 PFS (median) Not reached 92.2 months 0.008 PFS (3 years) 81% --</cell></row></table><note></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>Rituximab was kindly provided by Roche, Korea. We thank all patients and investigators involved in this study. Medical writing support (including the development of the draft outline and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact-checking, and referencing) was provided by Emma Prest, Ph.D. at Aspire Scientific Limited (Bollington, UK).</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head><p>AEs: adverse events; BM: bone marrow; CI: confidence interval; CISL: Consortium for Improving Survival of Lymphoma; CR: complete response; CT: computed tomography; ECOG PS: Eastern Clinical Oncology Group performance status; FL: follicular lymphoma; HR: hazard ratio; IELSG: International Extranodal Lymphoma Study Group; IWG: International Working Group; LDH: lactate dehydrogenase; MALT: mucosa-associated lymphoid tissue; MZL: marginal zone lymphoma; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NHL: non-Hodgkin's lymphoma; OS: overall survival; PD: progressive disease; PET: positron emission tomography; PFS: progression-free survival; PR: partial response; R-B: rituximab-bendamustine; R-Cb: rituximab-chlorambucil; R-CVP: rituximab, cyclophosphamide, vincristine, and prednisolone; SD: stable disease; TEAEs: treatment-emergent AEs; WHO: World Health Organization.</p><p>Authors' contributions SYO, WSK, and CS conceptualized and designed the study, coordinated, and supervised the data collection. SYO, and CS analyzed the data, drafted, and revised the manuscript. JSK, SJK, DHY, D-HY, WSL, HJK, H-YY, SHJ, JHW, SL, JHK, S-NL, JHJ, KAK, G-WL, JHL, HSL, and H-JS contributed to execute the clinical trial. All authors agreed to be responsible for all aspects of the study. All authors read and approved the final manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>This study was supported by the Dong-A University Research Fund. The study and manuscript were funded by the authors through the Dong-A University Research Fund. Rituximab was donated by Roche Korea.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p>The datasets obtained and analyzed during the present study are available from the corresponding author on reasonable request.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p>This trial was approved by the respective institutional review boards of all 18 participating centers. It was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice. All participating patients provided written informed consent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p>Not applicable.</p><p>Competing interests DHY has received research funding from Roche. All other authors declare that they have no competing interests.</p><p>• fast, convenient online submission</p><p>• thorough peer review by experienced researchers in your field</p><p>• rapid publication on acceptance</p><p>• support for research data, including large and complex data types</p><p>• gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p>At BMC, research is always in progress.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Learn more biomedcentral.com/submissions</head><p>Ready to submit your research ? Choose BMC and benefit from:</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin&apos;s lymphoma. The non-Hodgkin&apos;s lymphoma classification project</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="3909" to="3927" />
			<date type="published" when="1997" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">WHO classification of malignant lymphomas in Korea: report of the third nationwide study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Huh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.4132/koreanjpathol.2011.45.3.254</idno>
		<ptr target="https://doi.org/10.4132/koreanjpathol.2011.45.3.254" />
	</analytic>
	<monogr>
		<title level="j">J Pathol Transl Med</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="254" to="60" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Banks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Cleary</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1361" to="92" />
			<date type="published" when="1994" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Banks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Cleary</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Delsol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">De</forename><surname>Wolf-Peeters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Falini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="543" to="60" />
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Marginal zone lymphoma: old, new, targeted, and epigenetic therapies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Joshi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Sheikh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abbi</forename><forename type="middle">K</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Tulchinsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1177/2040620712453595</idno>
		<ptr target="https://doi.org/10.1177/2040620712453595" />
	</analytic>
	<monogr>
		<title level="j">Ther Adv Hematol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="275" to="90" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Olszewski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Castillo</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.27773</idno>
		<ptr target="https://doi.org/10.1002/cncr.27773" />
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="629" to="667" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Nongastric marginal zone B-cell lymphoma: analysis of 247 cases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Y</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">Y</forename><surname>Ryoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1002/ajh.20874</idno>
		<ptr target="https://doi.org/10.1002/ajh.20874" />
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="446" to="52" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Optimizing therapy for nodal marginal zone lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Thieblemont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Davi</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2015-12-624296</idno>
		<ptr target="https://doi.org/10.1182/blood-2015-12-624296" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2064" to="71" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Pathways towards indolent B-cell lymphoma-etiology and therapeutic strategies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Van Den Brand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Scheijen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jhj</forename><surname>Van Krieken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Groenen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.blre.2017.08.002</idno>
		<ptr target="https://doi.org/10.1016/j.blre.2017.08.002" />
	</analytic>
	<monogr>
		<title level="j">Blood Rev</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="426" to="461" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Ardeshna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Norton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">W</forename><surname>Hancock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Hoskin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Maclennan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="issue">9383</biblScope>
			<biblScope unit="page" from="516" to="538" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin&apos;s lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Feugier</surname></persName>
		</author>
		<idno type="DOI">10.2217/fon.15.57</idno>
		<ptr target="https://doi.org/10.2217/fon.15.57" />
	</analytic>
	<monogr>
		<title level="j">Future Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1327" to="1369" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">B-cell targeting in rheumatoid arthritis and other autoimmune diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cambridge</surname></persName>
		</author>
		<idno type="DOI">10.1038/nri1838</idno>
		<ptr target="https://doi.org/10.1038/nri1838" />
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="394" to="403" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Boye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Elter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Engert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="520" to="555" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Van Oers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Klasa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Marcus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kimby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2006-05-021113</idno>
		<ptr target="https://doi.org/10.1182/blood-2006-05-021113" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3295" to="301" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin&apos;s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Van Oers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Van Glabbeke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Giurgea</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Klasa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Marcus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wolf</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2009.26.5827</idno>
		<ptr target="https://doi.org/10.1200/JCO.2009.26.5827" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2853" to="2861" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Clinical activity of rituximab in gastric marginal zone non-Hodgkin&apos;s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Martinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Laszlo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Ferreri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Pruneri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ponzoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Conconi</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2005.08.128</idno>
		<ptr target="https://doi.org/10.1200/JCO.2005.08.128" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1979" to="83" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kalpadakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">A</forename><surname>Pangalis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">K</forename><surname>Angelopoulou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sachanas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">N</forename><surname>Kontopidou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Yiakoumis</surname></persName>
		</author>
		<idno type="DOI">10.1634/theoncologist.2012-0251</idno>
		<ptr target="https://doi.org/10.1634/theoncologist.2012-0251" />
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="190" to="197" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Conconi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Martinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Thieblemont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Ferreri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Devizzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Peccatori</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2002-11-3496-11-3496</idno>
		<ptr target="https://doi.org/10.1182/blood-2002-11-3496-11-3496" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2741" to="2746" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Salar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Domingo-Domenech</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Estany</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Canales</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Gallardo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Servitje</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.24605</idno>
		<ptr target="https://doi.org/10.1002/cncr.24605" />
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="5210" to="5217" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Friedberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Scofield</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Dal Cin</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2141.2009.07677.x</idno>
		<ptr target="https://doi.org/10.1111/j.1365-2141.2009.07677.x" />
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="741" to="749" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cervetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Galimberti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Sordi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Buda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Orciuolo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Cecconi</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdp395</idno>
		<ptr target="https://doi.org/10.1093/annonc/mdp395" />
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="851" to="855" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Orciuolo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Buda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Sordi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Barate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Galimberti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Ciancia</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.leukres.2009.04.003</idno>
		<ptr target="https://doi.org/10.1016/j.leukres.2009.04.003" />
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="184" to="193" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Addition of rituximab to chlorambucil produces superior eventfree survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Zucca</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Conconi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Laszlo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lopez-Guillermo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bouabdallah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2011.40.6272</idno>
		<ptr target="https://doi.org/10.1200/JCO.2011.40.6272" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="565" to="72" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of lymphoma (CISL) study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00277-011-1337-6</idno>
		<ptr target="https://doi.org/10.1007/s00277-011-1337-6" />
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="543" to="51" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Zucca</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Conconi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Martinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bouabdallah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Tucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Vitolo</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2016.70.6994</idno>
		<ptr target="https://doi.org/10.1200/JCO.2016.70.6994" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1905" to="1917" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Salar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Domingo-Domenech</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Panizo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Nicolas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bargay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Muntanola</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2352-3026(14)00021-0</idno>
		<ptr target="https://doi.org/10.1016/S2352-3026" />
	</analytic>
	<monogr>
		<title level="j">Lancet Haematol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="21" to="21" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Salar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Domingo-Domenech</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Panizo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Nicolas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bargay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Muntanola</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2017-07-795302</idno>
		<ptr target="https://doi.org/10.1182/blood-2017-07-795302" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1772" to="1776" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Salles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Offner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lopez-Guillermo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Belada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Xerri</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(10)62175-7</idno>
		<ptr target="https://doi.org/10.1016/S0140-6736" />
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="issue">9759</biblScope>
			<biblScope unit="page" from="62175" to="62182" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">A</forename><surname>Salles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Feugier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Offner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lopez-Guillermo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Belada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page">509</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: eastern Cooperative Oncology Group Protocol E4402</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">I</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Krauss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Habermann</surname></persName>
		</author>
		<idno type="DOI">10.1111/bjh.14007</idno>
		<ptr target="https://doi.org/10.1111/bjh.14007" />
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="867" to="75" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin&apos;s lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Hainsworth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Litchy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Shaffer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">L</forename><surname>Lackey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Grimaldi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">A</forename><surname>Greco</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2005.12.191</idno>
		<ptr target="https://doi.org/10.1200/JCO.2005.12.191" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1088" to="95" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Revised response criteria for malignant lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Pfistner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Juweid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Specht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Horning</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2006.09.2403</idno>
		<ptr target="https://doi.org/10.1200/JCO.2006.09.2403" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="579" to="86" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Optimal two-stage designs for phase II clinical trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Simon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Control Clin Trials</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="1989" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35/03</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Taverna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Martinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Hitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Mingrone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Pabst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Cevreska</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2015.61.3968</idno>
		<ptr target="https://doi.org/10.1200/JCO.2015.61.3968" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="495" to="500" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Rummel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Koenigsmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">U</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Knauf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Lerchenmuller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Losem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>Abstract 7515</note>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">Grade Lymphoma Study Group, Institute of Cancer Research UK. A study of obinutuzumab (RO5072759) plus chemotherapy in comparison with rituximab plus chemotherapy followed by obinutuzumab or rituximab maintenance in patients with untreated advanced indolent non-Hodgkin&apos;s lymphoma (GALLIUM)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hoffmann-La Roche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">German</forename><surname>Low</surname></persName>
		</author>
		<ptr target="https://ClinicalTrials.gov/show/NCT01332968.Accessed27" />
		<imprint>
			<date type="published" when="2018-06" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kalpadakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">A</forename><surname>Pangalis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sachanas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Tsirkinidis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">N</forename><surname>Kontopidou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Moschogiannis</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2018-02-833608</idno>
		<ptr target="https://doi.org/10.1182/blood-2018-02-833608" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="666" to="70" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
